Consumption of a Fermented Milk Product Containing Bifidobacterium lactis CNCM I-2494 in Women Complaining of Minor Digestive Symptoms: Rapid Response Which Is Independent of Dietary Fibre Intake or Physical Activity

Abstract

Background. Minor digestive symptoms are common and dietary approaches such as probiotic administration or fibre and fermentable carbohydrate intake adjustments are often recommended. A Fermented Milk Product (FMP) containing Bifidobacterium animalis subsp. lactis CNCM I-2494 and lactic acid bacteria has been shown to improve digestive symptoms after 4 weeks of consumption, but the speed of onset of this effect and its dependence on fibre intake or physical activity is unknown. To answer these questions, data from two previously published trials on FMP for minor digestive symptoms were combined. Methods. In total, 538 participants provided weekly assessments of bloating, abdominal pain/discomfort, flatulence, borborygmi/rumbling stomach from which a composite score was calculated. At baseline in one study (n = 336), dietary fibre consumption was recorded and physical activity classified as high, moderate or low. The speed of the FMP’s effect was assessed by a repeated measure analysis of variance measuring the change from baseline for the composite score of digestive symptoms. Results. FMP consumption resulted in a significant decrease in the composite score of symptoms after only 2 weeks in both studies and the pooled data at week 1 (−0.35 [−0.69, 0.00]; p = 0.05), week 2 (−0.66 [−1.04, −0.27]; p < 0.001), week 3 (−0.49 [−0.89, −0.10]; p = 0.01) and week 4 (−0.46 [−0.88, −0.04]; p = 0.03). The interactions fibre intake-by-product group, physical activity-by-product group and time-by-product group were not statistically significant. Conclusion. FMP consumption leads to a rapid improvement in symptoms which is likely to encourage adherence to this dietary intervention. This effect is independent of dietary fibre and physical activity.

Fermented milk containing Lactobacillus casei Zhang and Bifidobacterium animalis ssp. lactis V9 alleviated constipation symptoms through regulation of intestinal microbiota, inflammation, and metabolic pathways

“…The beneficial effects of probiotic fermented milk have been widely reported, such as elimination of pathogens (Corr et al, 2009;Piewngam et al, 2018;Piatek et al, 2019), inhibition of tumor development (Hendler and Zhang, 2018), improvement of symptoms of patients with irritable bowel syndrome (Guyonnet et al, 2007;Agrawal et al, 2009), and rapid improvement of minor digestive symptoms (Marteau et al, 2019). There are also various bioactive metabolites in fermented milk, such as bioactive peptides (Mohanty et al, 2016), conjugated linoleic acid, and exopolysaccharides, which protect the host against dysbiosis and inflammation (Fernandez and Marette, 2018;Baars et al, 2019).…”

A Fermented Milk Product with B. lactis CNCM I-2494 and Lactic Acid Bacteria Improves Gastrointestinal Comfort in Response to a Challenge Diet Rich in Fermentable Residues in Healthy Subjects

“…A fermented milk product containing Bifidobacterium animalis subsp. lactis CNCM I-2494 and lactic acid bacteria has been shown to improve symptoms and well-being in women with mild digestive complaints [12][13][14][15], and to improve bloating, digestive discomfort, and reduce abdominal distension in IBS-C patients [16,17]. The response to this product seems to be related to the metabolic activity of the gut microbiota [18].…”

Probiotic Supplements: Their Strategies in the Therapeutic and Prophylactic of Human Life-Threatening Diseases

“…As a result, probiotics may aid in the reduction of cell damage caused by inflammatory bowel disease [ 62 ]. In addition, Bifidobacterium infantis 35624 or Bifidobacterium lactis CNCM I-2494 combined with other probiotic strains, such as Streptococcus , Lactobacillus , and Lactococcus have been shown to relieve pain in people suffering from irritable bowel syndrome [ 63 , 64 ]. In contrast, using a single strain did not affect pain relief in more than 200 irritable bowel syndrome patients [ 65 ].…”